Towards optimal use of antithrombotic therapy of people with cancer at the end of life: A research protocol for the development and implementation of the SERENITY shared decision support tool

J Goedegebuur; D Abbel; S Accassat; W P Achterberg; A Akbari; V M Arfuch; E Baddeley; J J Bax; D Becker; B Bergmeijer; L Bertoletti; J W Blom; A Calvetti; S C Cannegieter; L Castro; N H Chavannes; N Coma-Auli; C Couffignal; A Edwards; M Edwards; H Enggaard; C Font; A Gava; G J Geersing; E C T Geijteman; S Greenley; C Gregory; J Gussekloo; I Hoffmann; A A Højen; W B van den Hout; M V Huisman; S Jacobsen; J Jagosh; M J Johnson; L Jørgensen; C C M Juffermans; E K Kempers; S Konstantinides; A F Kroder; M J H A Kruip; L Lafaie; J W Langendoen; T B Larsen; K Lifford; Y M van der Linden; I Mahé; L Maiorana; A Maraveyas; E S L Martens; D Mayeur; T E van Mens; K Mohr; S P Mooijaart; F E M Murtagh; A Nelson; P B Nielsen; A G Ording; M Ørskov; M Pearson; G Poenou; J E A Portielje; D Raczkiewicz; K Rasmussen; E Trinks-Roerdink; I Schippers; K Seddon; K Sexton; S Sivell; F Skjøth; M Søgaard; S Szmit; S Trompet; P Vassal; C Visser; L M van Vliet; E Wilson; F A Klok; S I R Noble

doi:10.1016/j.thromres.2023.05.008

Towards optimal use of antithrombotic therapy of people with cancer at the end of life: A research protocol for the development and implementation of the SERENITY shared decision support tool

J Goedegebuur, D Abbel, S Accassat, W P Achterberg, A Akbari, V M Arfuch, E Baddeley, J J Bax, D Becker, B Bergmeijer, L Bertoletti, J W Blom, A Calvetti, S C Cannegieter, L Castro, N H Chavannes, N Coma-Auli, C Couffignal, A Edwards, M EdwardsH Enggaard, C Font, A Gava, G J Geersing, E C T Geijteman, S Greenley, C Gregory, J Gussekloo, I Hoffmann, A A Højen, W B van den Hout, M V Huisman, S Jacobsen, J Jagosh, M J Johnson, L Jørgensen, C C M Juffermans, E K Kempers, S Konstantinides, A F Kroder, M J H A Kruip, L Lafaie, J W Langendoen, T B Larsen, K Lifford, Y M van der Linden, I Mahé, L Maiorana, A Maraveyas, E S L Martens, D Mayeur, T E van Mens, K Mohr, S P Mooijaart, F E M Murtagh, A Nelson, P B Nielsen, A G Ording, M Ørskov, M Pearson, G Poenou, J E A Portielje, D Raczkiewicz, K Rasmussen, E Trinks-Roerdink, I Schippers, K Seddon, K Sexton, S Sivell, F Skjøth, M Søgaard, S Szmit, S Trompet, P Vassal, C Visser, L M van Vliet, E Wilson, F A Klok, S I R Noble^*

^*Kontaktforfatter

Publikation: Bidrag til tidsskrift › Tidsskriftartikel › Forskning › peer review

7 Citationer (Scopus)

31 Downloads (Pure)

Abstract

Background
Even though antithrombotic therapy has probably little or even negative effects on the well-being of people with cancer during their last year of life, deprescribing antithrombotic therapy at the end of life is rare in practice. It is often continued until death, possibly resulting in excess bleeding, an increased disease burden and higher healthcare costs.

Methods
The SERENITY consortium comprises researchers and clinicians from eight European countries with specialties in different clinical fields, epidemiology and psychology. SERENITY will use a comprehensive approach combining a realist review, flash mob research, epidemiological studies, and qualitative interviews. The results of these studies will be used in a Delphi process to reach a consensus on the optimal design of the shared decision support tool. Next, the shared decision support tool will be tested in a randomised controlled trial. A targeted implementation and dissemination plan will be developed to enable the use of the SERENITY tool across Europe, as well as its incorporation in clinical guidelines and policies. The entire project is funded by Horizon Europe.

Results
SERENITY will develop an information-driven shared decision support tool that will facilitate treatment decisions regarding the appropriate use of antithrombotic therapy in people with cancer at the end of life.

Conclusions
We aim to develop an intervention that guides the appropriate use of antithrombotic therapy, prevents bleeding complications, and saves healthcare costs. Hopefully, usage of the tool leads to enhanced empowerment and improved quality of life and treatment satisfaction of people with advanced cancer and their care givers.

Originalsprog	Engelsk
Tidsskrift	Thrombosis Research
Vol/bind	228
Sider (fra-til)	54-60
Antal sider	7
ISSN	0049-3848
DOI	https://doi.org/10.1016/j.thromres.2023.05.008
Status	Udgivet - aug. 2023

Bibliografisk note

Adgang til dokumentet

10.1016/j.thromres.2023.05.008Licens: CC BY 4.0

Open Access articleForlagets udgivne version, 708 KBLicens: CC BY 4.0

AUB Link

Søg efter materialet i Aalborg Universitetsbiblioteks søgemaskine

Andre filer og links

Link to publication in Scopus

Citationsformater

Goedegebuur, J., Abbel, D., Accassat, S., Achterberg, W. P., Akbari, A., Arfuch, V. M., Baddeley, E., Bax, J. J., Becker, D., Bergmeijer, B., Bertoletti, L., Blom, J. W., Calvetti, A., Cannegieter, S. C., Castro, L., Chavannes, N. H., Coma-Auli, N., Couffignal, C., Edwards, A., ... Noble, S. I. R. (2023). Towards optimal use of antithrombotic therapy of people with cancer at the end of life: A research protocol for the development and implementation of the SERENITY shared decision support tool. Thrombosis Research, 228, 54-60. https://doi.org/10.1016/j.thromres.2023.05.008

@article{8d8a07e4b7844ce2a011ca202b9ffae6,

title = "Towards optimal use of antithrombotic therapy of people with cancer at the end of life: A research protocol for the development and implementation of the SERENITY shared decision support tool",

abstract = "BackgroundEven though antithrombotic therapy has probably little or even negative effects on the well-being of people with cancer during their last year of life, deprescribing antithrombotic therapy at the end of life is rare in practice. It is often continued until death, possibly resulting in excess bleeding, an increased disease burden and higher healthcare costs.MethodsThe SERENITY consortium comprises researchers and clinicians from eight European countries with specialties in different clinical fields, epidemiology and psychology. SERENITY will use a comprehensive approach combining a realist review, flash mob research, epidemiological studies, and qualitative interviews. The results of these studies will be used in a Delphi process to reach a consensus on the optimal design of the shared decision support tool. Next, the shared decision support tool will be tested in a randomised controlled trial. A targeted implementation and dissemination plan will be developed to enable the use of the SERENITY tool across Europe, as well as its incorporation in clinical guidelines and policies. The entire project is funded by Horizon Europe.ResultsSERENITY will develop an information-driven shared decision support tool that will facilitate treatment decisions regarding the appropriate use of antithrombotic therapy in people with cancer at the end of life.ConclusionsWe aim to develop an intervention that guides the appropriate use of antithrombotic therapy, prevents bleeding complications, and saves healthcare costs. Hopefully, usage of the tool leads to enhanced empowerment and improved quality of life and treatment satisfaction of people with advanced cancer and their care givers.",

keywords = "Death, Fibrinolytic Agents/therapeutic use, Humans, Neoplasms/drug therapy, Palliative Care, Quality of Life, Randomized Controlled Trials as Topic, Anticoagulants, Hemorrhage, Thrombosis, Neoplasms, Deprescriptions, Palliative care",

author = "J Goedegebuur and D Abbel and S Accassat and Achterberg, {W P} and A Akbari and Arfuch, {V M} and E Baddeley and Bax, {J J} and D Becker and B Bergmeijer and L Bertoletti and Blom, {J W} and A Calvetti and Cannegieter, {S C} and L Castro and Chavannes, {N H} and N Coma-Auli and C Couffignal and A Edwards and M Edwards and H Enggaard and C Font and A Gava and Geersing, {G J} and Geijteman, {E C T} and S Greenley and C Gregory and J Gussekloo and I Hoffmann and H{\o}jen, {A A} and {van den Hout}, {W B} and Huisman, {M V} and S Jacobsen and J Jagosh and Johnson, {M J} and L J{\o}rgensen and Juffermans, {C C M} and Kempers, {E K} and S Konstantinides and Kroder, {A F} and Kruip, {M J H A} and L Lafaie and Langendoen, {J W} and Larsen, {T B} and K Lifford and {van der Linden}, {Y M} and I Mah{\'e} and L Maiorana and A Maraveyas and Martens, {E S L} and D Mayeur and {van Mens}, {T E} and K Mohr and Mooijaart, {S P} and Murtagh, {F E M} and A Nelson and Nielsen, {P B} and Ording, {A G} and M {\O}rskov and M Pearson and G Poenou and Portielje, {J E A} and D Raczkiewicz and K Rasmussen and E Trinks-Roerdink and I Schippers and K Seddon and K Sexton and S Sivell and F Skj{\o}th and M S{\o}gaard and S Szmit and S Trompet and P Vassal and C Visser and {van Vliet}, {L M} and E Wilson and Klok, {F A} and Noble, {S I R}",

year = "2023",

month = aug,

doi = "10.1016/j.thromres.2023.05.008",

language = "English",

volume = "228",

pages = "54--60",

journal = "Thrombosis Research",

issn = "0049-3848",

publisher = "Elsevier",

}

Goedegebuur, J, Abbel, D, Accassat, S, Achterberg, WP, Akbari, A, Arfuch, VM, Baddeley, E, Bax, JJ, Becker, D, Bergmeijer, B, Bertoletti, L, Blom, JW, Calvetti, A, Cannegieter, SC, Castro, L, Chavannes, NH, Coma-Auli, N, Couffignal, C, Edwards, A, Edwards, M, Enggaard, H, Font, C, Gava, A, Geersing, GJ, Geijteman, ECT, Greenley, S, Gregory, C, Gussekloo, J, Hoffmann, I, Højen, AA, van den Hout, WB, Huisman, MV, Jacobsen, S, Jagosh, J, Johnson, MJ, Jørgensen, L, Juffermans, CCM, Kempers, EK, Konstantinides, S, Kroder, AF, Kruip, MJHA, Lafaie, L, Langendoen, JW, Larsen, TB, Lifford, K, van der Linden, YM, Mahé, I, Maiorana, L, Maraveyas, A, Martens, ESL, Mayeur, D, van Mens, TE, Mohr, K, Mooijaart, SP, Murtagh, FEM, Nelson, A, Nielsen, PB , Ording, AG , Ørskov, M, Pearson, M, Poenou, G, Portielje, JEA, Raczkiewicz, D, Rasmussen, K, Trinks-Roerdink, E, Schippers, I, Seddon, K, Sexton, K, Sivell, S, Skjøth, F , Søgaard, M, Szmit, S, Trompet, S, Vassal, P, Visser, C, van Vliet, LM, Wilson, E, Klok, FA & Noble, SIR 2023, 'Towards optimal use of antithrombotic therapy of people with cancer at the end of life: A research protocol for the development and implementation of the SERENITY shared decision support tool', Thrombosis Research, bind 228, s. 54-60. https://doi.org/10.1016/j.thromres.2023.05.008

Towards optimal use of antithrombotic therapy of people with cancer at the end of life: A research protocol for the development and implementation of the SERENITY shared decision support tool. / Goedegebuur, J; Abbel, D; Accassat, S et al.
I: Thrombosis Research, Bind 228, 08.2023, s. 54-60.

Publikation: Bidrag til tidsskrift › Tidsskriftartikel › Forskning › peer review

TY - JOUR

T1 - Towards optimal use of antithrombotic therapy of people with cancer at the end of life

T2 - A research protocol for the development and implementation of the SERENITY shared decision support tool

AU - Goedegebuur, J

AU - Abbel, D

AU - Accassat, S

AU - Achterberg, W P

AU - Akbari, A

AU - Arfuch, V M

AU - Baddeley, E

AU - Bax, J J

AU - Becker, D

AU - Bergmeijer, B

AU - Bertoletti, L

AU - Blom, J W

AU - Calvetti, A

AU - Cannegieter, S C

AU - Castro, L

AU - Chavannes, N H

AU - Coma-Auli, N

AU - Couffignal, C

AU - Edwards, A

AU - Edwards, M

AU - Enggaard, H

AU - Font, C

AU - Gava, A

AU - Geersing, G J

AU - Geijteman, E C T

AU - Greenley, S

AU - Gregory, C

AU - Gussekloo, J

AU - Hoffmann, I

AU - Højen, A A

AU - van den Hout, W B

AU - Huisman, M V

AU - Jacobsen, S

AU - Jagosh, J

AU - Johnson, M J

AU - Jørgensen, L

AU - Juffermans, C C M

AU - Kempers, E K

AU - Konstantinides, S

AU - Kroder, A F

AU - Kruip, M J H A

AU - Lafaie, L

AU - Langendoen, J W

AU - Larsen, T B

AU - Lifford, K

AU - van der Linden, Y M

AU - Mahé, I

AU - Maiorana, L

AU - Maraveyas, A

AU - Martens, E S L

AU - Mayeur, D

AU - van Mens, T E

AU - Mohr, K

AU - Mooijaart, S P

AU - Murtagh, F E M

AU - Nelson, A

AU - Nielsen, P B

AU - Ording, A G

AU - Ørskov, M

AU - Pearson, M

AU - Poenou, G

AU - Portielje, J E A

AU - Raczkiewicz, D

AU - Rasmussen, K

AU - Trinks-Roerdink, E

AU - Schippers, I

AU - Seddon, K

AU - Sexton, K

AU - Sivell, S

AU - Skjøth, F

AU - Søgaard, M

AU - Szmit, S

AU - Trompet, S

AU - Vassal, P

AU - Visser, C

AU - van Vliet, L M

AU - Wilson, E

AU - Klok, F A

AU - Noble, S I R

PY - 2023/8

Y1 - 2023/8

N2 - BackgroundEven though antithrombotic therapy has probably little or even negative effects on the well-being of people with cancer during their last year of life, deprescribing antithrombotic therapy at the end of life is rare in practice. It is often continued until death, possibly resulting in excess bleeding, an increased disease burden and higher healthcare costs.MethodsThe SERENITY consortium comprises researchers and clinicians from eight European countries with specialties in different clinical fields, epidemiology and psychology. SERENITY will use a comprehensive approach combining a realist review, flash mob research, epidemiological studies, and qualitative interviews. The results of these studies will be used in a Delphi process to reach a consensus on the optimal design of the shared decision support tool. Next, the shared decision support tool will be tested in a randomised controlled trial. A targeted implementation and dissemination plan will be developed to enable the use of the SERENITY tool across Europe, as well as its incorporation in clinical guidelines and policies. The entire project is funded by Horizon Europe.ResultsSERENITY will develop an information-driven shared decision support tool that will facilitate treatment decisions regarding the appropriate use of antithrombotic therapy in people with cancer at the end of life.ConclusionsWe aim to develop an intervention that guides the appropriate use of antithrombotic therapy, prevents bleeding complications, and saves healthcare costs. Hopefully, usage of the tool leads to enhanced empowerment and improved quality of life and treatment satisfaction of people with advanced cancer and their care givers.

AB - BackgroundEven though antithrombotic therapy has probably little or even negative effects on the well-being of people with cancer during their last year of life, deprescribing antithrombotic therapy at the end of life is rare in practice. It is often continued until death, possibly resulting in excess bleeding, an increased disease burden and higher healthcare costs.MethodsThe SERENITY consortium comprises researchers and clinicians from eight European countries with specialties in different clinical fields, epidemiology and psychology. SERENITY will use a comprehensive approach combining a realist review, flash mob research, epidemiological studies, and qualitative interviews. The results of these studies will be used in a Delphi process to reach a consensus on the optimal design of the shared decision support tool. Next, the shared decision support tool will be tested in a randomised controlled trial. A targeted implementation and dissemination plan will be developed to enable the use of the SERENITY tool across Europe, as well as its incorporation in clinical guidelines and policies. The entire project is funded by Horizon Europe.ResultsSERENITY will develop an information-driven shared decision support tool that will facilitate treatment decisions regarding the appropriate use of antithrombotic therapy in people with cancer at the end of life.ConclusionsWe aim to develop an intervention that guides the appropriate use of antithrombotic therapy, prevents bleeding complications, and saves healthcare costs. Hopefully, usage of the tool leads to enhanced empowerment and improved quality of life and treatment satisfaction of people with advanced cancer and their care givers.

KW - Death

KW - Fibrinolytic Agents/therapeutic use

KW - Humans

KW - Neoplasms/drug therapy

KW - Palliative Care

KW - Quality of Life

KW - Randomized Controlled Trials as Topic

KW - Anticoagulants

KW - Hemorrhage

KW - Thrombosis

KW - Neoplasms

KW - Deprescriptions

KW - Palliative care

UR - http://www.scopus.com/inward/record.url?scp=85164232931&partnerID=8YFLogxK

U2 - 10.1016/j.thromres.2023.05.008

DO - 10.1016/j.thromres.2023.05.008

M3 - Journal article

C2 - 37276718

SN - 0049-3848

VL - 228

SP - 54

EP - 60

JO - Thrombosis Research

JF - Thrombosis Research

ER -

Towards optimal use of antithrombotic therapy of people with cancer at the end of life: A research protocol for the development and implementation of the SERENITY shared decision support tool

Abstract

Bibliografisk note

Adgang til dokumentet

AUB Link

Andre filer og links

Fingeraftryk

Citationsformater